Equities research analysts at Lazard Capital initiated coverage on shares of Allscripts Healthcare Solutions (NASDAQ: MDRX) in a research note issued to investors on Wednesday. The firm set a “neutral” rating on the stock.
Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of Allscripts Healthcare Solutions from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, May 17th. They now have a $11.00 price target on the stock. Separately, analysts at Raymond James (NYSE: RJF) downgraded shares of Allscripts Healthcare Solutions from an “outperform” rating to a “market perform” rating in a research note to investors on Monday, April 30th. Finally, analysts at Goldman Sachs (NYSE: GS) cut their price target on shares of Allscripts Healthcare Solutions from $21.00 to $13.00 in a research note to investors on Sunday, April 29th. They now have a “neutral” rating on the stock.
Allscripts Healthcare Solutions traded down 1.09% on Wednesday, hitting $10.93. Allscripts Healthcare Solutions has a 52-week low of $8.99 and a 52-week high of $21.92. The company has a market cap of $2.083 billion and a price-to-earnings ratio of 31.57.
Allscripts Healthcare Solutions last released its earnings data on Thursday, April 26th. The company reported $0.12 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.24 by $0.12. Allscripts Healthcare Solutions’s revenue was up 8.8% compared to the same quarter last year. Analysts expect that Allscripts Healthcare Solutions will post $0.20 EPS next quarter.
Allscripts Healthcare Solutions, Inc. (Allscripts) is a provider of clinical, financial, connectivity and information solutions and related professional services to hospitals, physicians and post-acute organizations.